Comparative Pharmacology
Head-to-head clinical analysis: CARDENE SR versus CARTIA XT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARDENE SR versus CARTIA XT.
CARDENE SR vs CARTIA XT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nicardipine is a dihydropyridine calcium channel blocker that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. It produces relaxation of coronary vascular smooth muscle and dilation of coronary arteries, and also dilates peripheral arteries, reducing systemic vascular resistance and blood pressure.
Diltiazem, a benzothiazepine calcium channel blocker, inhibits calcium ion influx across cardiac and vascular smooth muscle cells during depolarization, leading to vasodilation and reduced myocardial contractility and conduction velocity, particularly at the AV node.
Initial: 30 mg orally twice daily (SR capsules). Titrate up to 60 mg twice daily. Usual maintenance: 30-60 mg twice daily.
Diltiazem hydrochloride extended-release capsules (CARTIA XT) are administered orally. For hypertension and angina, the typical adult dose is 180–360 mg once daily, initially 180 mg once daily, titrated to response.
None Documented
None Documented
Terminal elimination half-life 8.6 hours (range 6-15 hours). Clinical context: No accumulation at steady state with TID dosing.
Terminal half-life 3-4.5 hours; prolonged in hepatic impairment (up to 15 hours) or with cimetidine.
Renal: 60% (metabolites, unchanged drug <1%); Biliary/Fecal: 35%
Renal (biliary/fecal minimal). 70-80% excreted as inactive metabolites in urine; 15% unchanged.
Category C
Category C
Calcium Channel Blocker
Calcium Channel Blocker